This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

milvexian
Medical Information

Milvexian - Prevention of Venous Thromboembolism in Patients Undergoing Elective Knee Arthroplasty – AXIOMATIC-TKR

Last Updated: 11/20/2026

SUMMARY  

  • AXIOMATIC-TKR was a randomized, parallel-group, adaptive design, phase 2 study to compare 7 milvexian regimens (25 mg, 50 mg, 100 mg or 200 mg twice-daily or 25 mg, 50 mg, or 200 mg once daily) with enoxaparin (40 mg once daily) in patients undergoing elective knee arthroplasty.1
  • The primary efficacy outcome of venous thromboembolism occurred in 27 of 129 (21%), 14 of 124 (11%), 12 of 134 (9%), and 10 of 131 patients (8%) given 25 mg, 50 mg, 100 mg, or 200 mg of milvexian twice-daily, and 7 of 28 (25%), 30 of 127 (24%), and 8 of 123 patients (7%) given 25 mg, 50 mg or 200 mg of milvexian once daily, as compared with 54 of 252 patients (21%) given enoxaparin. The dose response with twice-daily milvexian was significant (P<0.001, 1-sided).1
  • The principal safety outcome of any bleeding occurred in 38 of 923 patients (4%) given milvexian and 12 of 296 patients (4%) given enoxaparin, major or clinically relevant nonmajor bleeding occurred in 1% and 2%, respectively, and serious adverse events were reported in 2% and 4%, respectively.1

BRISTOL MYERS SQUIBB AND JOHNSON & JOHNSON COLLABORATION

Milvexian is an oral investigational factor XIa inhibitor being studied for the prevention of major thrombotic conditions in a worldwide collaboration program between Bristol Myers Squibb and Johnson & Johnson. Milvexian is not currently approved for any use.

To read more about how Johnson & Johnson processes personal data, please visit https://innovativemedicine.jnj.com, select your country or region (in the upper right corner), and then click on Privacy Policy.

To read more about how Bristol Myers Squibb processes personal data, please visit https://www.bms.com, select your country (in the upper right corner), and then click on Privacy Policy.

CLINICAL DATA

AXIOMATIC-TKR

AXIOMATIC-TKR1 was a randomized, parallel-group, adaptive design, phase 2 study with blinded outcome adjudication to compare 7 milvexian regimens (25 mg, 50 mg, 100 mg or 200 mg twice-daily or 25 mg, 100 mg, or 200 mg once daily) with enoxaparin (40 mg once daily) in patients undergoing knee arthroplasty.

Study Design/Methods

  • Key eligibility criteria included patients undergoing elective unilateral total knee arthroplasty who were 50 years of age or older, medically stable, and appropriate candidates for anticoagulant prophylaxis.
  • Key exclusion criteria were contraindications to enoxaparin (e.g., creatinine clearance < 30 mL/minute), a history of severe hepatic impairment or prior venous thromboembolism, the use of long-term antithrombotic therapy other than aspirin (≤100 mg per day), or the inability to undergo venography.
  • Dosing interventions
    • Initially, eligible patients were randomly assigned, in a 1:1:1:1:1:1:2 ratio, to one of seven parallel treatment groups, which included four twice daily milvexian regimens (25 mg, 50 mg, 100 mg, or 200 mg), two once daily milvexian regimens (25 mg or 200 mg), and enoxaparin, respectively.
    • As a result of an ad hoc analysis conducted by the trial’s Operations Committee (which functioned as an independent data monitoring committee), enrollment into the 25 mg once daily milvexian group was stopped because the point estimate for the rate of venous thromboembolism (25%) met the prespecified criteria for insufficient efficacy. A milvexian 50 mg once daily regimen was added to gain more information about the efficacy and safety of once daily versus twice daily milvexian dosing.
    • Oral milvexian or matching placebo, or enoxaparin, 40 mg once daily subcutaneously was started 12 to 24 hours after surgery. A single dose of subcutaneous enoxaparin was allowed the evening before surgery according to local standard-of-care.
    • Treatment with milvexian or enoxaparin was given for 10 to 14 days after surgery.
    • Treatment assignment to milvexian or enoxaparin was open label, but patient and observer were blinded to milvexian dose regimen. Patients in the milvexian groups were asked to take a total of four capsules (active drug or matching placebo) per day, two capsules in the morning and two capsules in the evening.
  • Primary efficacy outcome was venous thromboembolism, defined as the composite of asymptomatic deep-vein thrombosis (detected by mandatory unilateral venography performed 10 to 14 days after surgery), confirmed symptomatic venous thromboembolism (symptomatic deep-vein thrombosis of the leg or nonfatal pulmonary embolism), or death.
  • Principal safety outcome was any bleeding, defined as the composite of major, clinically relevant nonmajor, and minimal bleeding. Secondary safety outcomes were: (a) major bleeding, (b) clinically relevant nonmajor bleeding, (c) clinically relevant bleeding, defined as the composite of major and clinically relevant nonmajor bleeding, and (d) minimal bleeding.
    • Bleeding definitions2:
      • Major bleeding (International Society on Thrombosis and Haemostasis [ISTH] criteria in the surgical setting):
        • Fatal bleeding, and/or
        • Bleeding that is symptomatic and occurs in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, pericardial, in a non‐operated joint, or intramuscular with compartment syndrome, and/or
        • Extra surgical site bleeding causing a fall in hemoglobin level of ≥ 2.0 g/dL (1.24 mmol/L), or leading to transfusion of ≥ 2 units of whole blood or packed red blood cells, with temporal association within 24 to 48 hours to the bleeding, and/or
        • Surgical site bleeding that requires a second intervention (open, arthroscopic, endovascular), or a hemarthrosis of sufficient size as to interfere with rehabilitation by delaying mobilization or delayed wound healing resulting in prolonged hospitalization or a deep wound infection, and/or
        • Surgical site bleeding that is unexpected and prolonged and/or sufficiently large to cause hemodynamic instability; there should be an associated fall in Hemoglobin level of ≥2.0 g/dL) (1.24 mmol/L), or transfusion, indicated by the bleeding, of at least 2 units of whole blood or packed red blood cells, with temporal association within 24 hours to the bleeding
      • Clinically relevant nonmajor bleeding:
        • Overt bleeding not meeting the criteria for major bleeding, but that resulted in medical examination, intervention, or had clinical consequences for a patient
      • Minimal bleeding:
        • Any bleeding event that does not fulfill the criteria for a major or clinically relevant nonmajor bleeding mobilization or wound healing and resulted in prolonged hospitalization or deep wound infection.

Results

  • A total of 1242 patients from 118 centers in 18 countries were randomized.
Baseline Characteristics

Demographics and Clinical Characteristics of the Patients1,a
Characteristic
Milvexian Twice Daily
Milvexian Once Daily
Enoxaparin
25 mg
50 mg
100 mg
200 mg
25 mg
50 mg
200 mg
40 mg
Modified intention-to-treat population, n
129
124
134
131
28
127
123
252
Age, years, median (range)
69
(51-87)

68
(51-87)

67
(50-86)

69
(50-86)

67
(55-77)

68
(50-88)

68
(50-88)

68
(50-90)

Female sex, n (%)
92
(71)

89
(72)

88
(66)

89
(68)

18
(64)

92
(72)

88
(72)

171
(68)

Race, n (%)b
   White
112
(87)

107
(86)

117
(87)

116
(89)

28
(100)

103
(81)

105
(85)

216
(86)

   Asian
16
(12)

15
(12)

14
(10)

14
(11)

0
21
(17)

15
(12)

29
(12)

   Black
1
(1)

1
(1)

3
(2)

1
(1)

0
0
0
3
(1)

   Other
0
1
(1)

0
0
0
0
3
(2)

2
(1)

Weight, kg, median (range)
83
(40-150)

79
(44-150)

85
(48-130)

84
(42-132)

82
(56-134)

80
(48-181)

82
(48-129)

81
(41-146)

Creatinine clearance,c mL/min, median (interquartile range)
86
(71-109)

92
(75-113)

90
(70-118)

94
(70-114)

95
(72-127)

88
(70-105)

91
(73-115)

92
(72-114)

Preoperative enoxaparin, n (%)
8
(6)

9
(7)

8
(6)

7
(5)

2
(7)

10
(8)

11
(9)

28
(11)

Type of anesthesia,d n (%)
   General
29
(22)

25
(20)

31
(23)

34
(26)

5
(18)

29
(23)

26
(21)

57
(23)

   Spinal
99
(77)

99
(80)

102
(76)

96
(73)

23
(82)

101
(80)

99
(80)

194
(77)

   Epidural
4
(3)

5
(4)

5
(4)

4
(3)

0
6
(5)

3
(2)

7
(3)

   Regional
20
(16)

33
(27)

42
(31)

33
(25)

6
(21)

33
(26)

29
(24)

58
(23)

   Other  
2
(2)

4
(3)

3
(2)

4
(3)

0
1
(1)

4
(3)

9
(4)

Duration of surgery, hours, median (range)
1.3
(0.5-3.5)

1.4
(0.7-3.1)

1.4
(0.5-6.6)

1.4
(0.6-2.8)

1.4
(0.8-2.8)

1.4
(0.6-3.3)

1.4
(0.7-3.5)

1.4
(0.4-3.5)

Tourniquet use, n (%)
89
(69)

88
(71)

98
(73)

84
(64)

20
(71)

93
(73)

84
(68)

188
(75)

Duration of tourniquet use, hours, median (range)
1.2
(0.3-15)

1.1
(0.2-23)

1.2
(0.3-10)

1.1
(0.4-10)

1.3
(0.2-19)

1.2
(0.3-20)

1.3
(0.3-15)

1.2
(0.2-15)

Time after surgery to ambulation, days, median (range)
1
(0-3)

1
(0-3)

1
(0-4)

1
(0-4)

1
(0-4)

1
(0-4)

1
(0-6)

1
(0-4)

Baseline factor XI clotting activity,e %, median (interquartile range)
109
(94-127)

107
(91-119)

104
(93-119)

110
(95-124)

107
(89-116)

100
(87-117)

102
(87-113)

114
(100-131)

Baseline activated partial-thrombo-plastin time, seconds,f median (interquartile range)
26
(24-28)

27
(25-29)

26
(25-28)

26
(24-28)

26
(25-28)

26
(25-29)

26
(25-28)

26
(25-28)

Safety population, n
148
148
149
148
33
150
147
296
Time after surgery to milvexian or enoxaparin administration, hours, median (range)
22
(13-26)

22
(13-26)

22
(13-25)

22
(12-26)

22
(13-25)

22
(13-26)

23
(14-26)

22
(7-34)

Duration of milvexian or enoxaparin treatment, days, median (range)
12
(1-16)

12
(2-16)

12
(4-17)

12
(4-16)

12
(9-14)

13
(6-16)

12
(1-16)

12
(1-15)

aThe modified intention-to-treat population included all patients who received at least 1 dose of trial medication and had a venogram within the prespecified time window that could be evaluated, a documented symptomatic venous thromboembolic event, or a fatal event. The safety population consisted of all patients who received at least 1 dose of trial medication. Percentages may not total 100 because of rounding.bRace was reported by the patient. Three patients in the group receiving 50 mg of milvexian once daily and 2 in the enoxaparin group chose not to report information on race.cCreatinine clearance values were calculated using the Cockcroft and Gault equation.dPatients may have undergone more than 1 type of anesthesia.eThe normal range for factor XI clotting activity is 60%-150%.fThe normal range for the activated partial-thromboplastin time is 22-29 seconds.
Outcomes
  • The primary efficacy outcome of venous thromboembolism occurred in 27 of 129 patients (21%), 14 of 124 patients (11%), 12 of 134 patients (9%) and 10 of 131 patients (8%) in the 25 mg, 50 mg, 100 mg and 200 mg twice daily milvexian groups, respectively; consistent with a significant dose-response relationship (one-sided P<0.001). In the twice daily milvexian group the primary efficacy outcome occurred in 63 of 518 patients (12%), significantly lower (P<0.001, 1-sided) than the prespecified benchmark of 30%. For the once daily milvexian regimens there was a statistically significant (P<0.001, 1-sided) dose-response for the primary efficacy outcome.
  • For efficacy outcomes, see Table: Efficacy Outcomes.

Efficacy Outcomes1,a
Milvexian Twice Daily
Milvexian Once Daily
Enoxaparin
25 mg
50 mg
100 mg
200 mg
25 mg
50 mg
200 mg
40 mg
n
129
124
134
131
28
127
123
252
Primary efficacy outcome: venous thromboembolismb
   Any event, n (%)
27
(21)

14
(11)

12
(9)

10
(8)

7
(25)

30
(24)

8
(7)

54
(21)

      Milvexian vs
      enoxaparin,
      relative risk,
      (95% CI)

0.97
(0.65-1.45)

0.53
(0.31-0.90)

0.42
(0.23-0.76)

0.37
(0.19-0.69)

1.00
(0.51-1.97)

1.15
(0.78-1.70)

0.30
(0.15-0.62)

NA
Components of the primary efficacy outcome,c n
   Death from any
   cause

0
0
0
0
0
0
0
1
   Nonfatal
   pulmonary
   embolism

0
1
1
0
0
0
0
1
   Symptomatic
   distal deep-vein
   thrombosis

0
0
1
0
0
2
0
0
   Asymptomatic
   proximal deep
   vein thrombosis

1
0
1
0
0
2
0
2
   Asymptomatic
   distal deep-vein
   thrombosis

26
13
9
10
7
26
8
50
Abbreviations: CI, confidence interval; NA, not applicable.aEfficacy outcomes were assessed in the modified intent-to-treat population, which included all patients who received at least 1 dose of trial medication and had a venogram within the prespecified time window that could be evaluated, a documented symptomatic venous thromboembolic event, or a fatal event. bVenous thromboembolism was defined as the composite of asymptomatic deep-vein thrombosis (detected by mandatory unilateral venography performed 10-14 days after surgery), confirmed symptomatic venous thromboembolism (symptomatic deep-vein thrombosis of the leg or nonfatal pulmonary embolism), or death from any cause.cThere were no cases of symptomatic proximal deep-vein thrombosis.
  • The principal safety outcome, any bleeding, occurred in 4% (38/923) of patients given milvexian and 4% (12/296) of patients given enoxaparin. Most bleeding episodes were in the minimal category and involved the surgical site. There was 1 major bleeding event with enoxaparin and none with milvexian. Rates of clinically relevant bleeding were 1% and 2% with milvexian and enoxaparin, respectively.
  • Serious adverse events were reported in 2% (22/923) of patients versus 4% (11/296) of patients given milvexian and enoxaparin, respectively.
  • For safety outcomes, see Table: Safety Outcomes
  • The activated partial-thromboplastin time ratio was increased in a dose-dependent manner in the milvexian group, but no apparent effect was observed with enoxaparin.
  • Milvexian demonstrated no evidence of a dose-dependent increase in bleeding.
  • Neither enoxaparin nor milvexian increased the prothrombin time ratio.

Safety Outcomes1,a
Milvexian Twice Daily
Milvexian Once Daily
Enoxaparin
25 mg
50 mg
100 mg
200 mg
25 mg
50 mg
200 mg
40 mg
n
148
148
149
148
33
150
147
296
Any bleeding, n (%)
2
(1)

7
(5)

7
(5)

5
(3)

0
8
(5)

9
(6)

12
(4)

   Milvexian vs
   enoxaparin,
   relative risk
   (95% CI)

0.33
(0.08-1.43)

1.15
(0.47-2.82)

1.14
(0.47-2.80)

0.81
(0.29-2.24)

0
(NA)

1.17
(0.50-2.72)

1.51
(0.66-3.43)

NA
Major or clinically relevant nonmajor bleeding, n (%)
0
2
(1)

1
(1)

1
(1)

0
2
(1)

1
(1)

5
(2)

   Milvexian vs
   enoxaparin,
   relative risk
   (95% CI)

0
(NA)

0.79
(0.16-3.96)

0.39
(0.05-3.30)

0.39
(0.05-3.28)

0
(NA)

0.68
(0.14-3.39)

0.40
(0.05-3.34)

NA
Major bleeding, n (%)
0
0
0
0
0
0
0
1
(<1)b

Clinically relevant nonmajor bleeding, n (%)
0
2
(1)

1
(1)

1
(1)

0
2
(1)

1
(1)

4
(1)

Serious adverse event, n (%)
5
(3)

5
(3)

5
(3)

2
(1)

1
(3)

2
(1)

2
(1)

11
(4)

At least 1 adverse event, n (%)
56
(38)

67
(45)

51
(34)

54
(36)

7
(21)

58
(39)

65
(44)

113
(38)

Adverse event leading to discontinuation of treatment, n (%)
2
(1)

7
(5)

2
(1)

4
(3)

0
4
(3)

6
(4)

8
(3)

Abbreviations: CI, confidence interval; NA, not applicable.aSafety outcomes were assessed in the safety population, which included all the patients who had received at least 1 dose of a trial medication; the time for analysis included the period during which a trial medication was administered plus 2 days.bSpontaneous subdural hematoma with decreased level of consciousness.

Limitations

  • The strength of the conclusion regarding the low rate of clinically relevant bleeding with milvexian is limited by the modest sample size
    • Further studies are needed to confirm the safety of milvexian alone or in combination with antiplatelet drugs
  • The trial was open label with respect to assignment to milvexian or enoxaparin
    • To minimize bias, the trial was blinded with respect to assignment to a milvexian regimen, and all outcomes were adjudicated by a committee whose members were unaware of treatment assignment  
  • With the open-label design, a potential for bias in favor of enoxaparin existed because the criteria for minimal bleeding depended on investigator reporting of more than expected bleeding.

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT® (and/or other resources, including internal/external databases) was conducted on 16 July 2026.

References

1 Weitz JI, Strony J, Ageno W, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med. 2021;385(23):2161-2172.  
2 Weitz JI, Strony J, Ageno W, et al. Supplement to: Milvexian for the prevention of venous thromboembolism. N Engl J Med. 2021;385(23):2161-2172.   

Would you like to clear and leave your conversation? Message history will be lost.